drugset / Trial / NCT02638909
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Phase 2
Terminated
4 enrolled
Criterium, Inc.
Novartis · collabUniversity of Colorado, Denver · collab
NaSingle-groupOpen-labelTreatment
Summary
The available data indicate that Ceritinib has substantial anti-tumor activity in patients with anaplastic lymphoma kinase (ALK) and ROS1 rearranged non-small cell lung cancer (NSCLC). This trial will investigate the potential of Ceritinib in patients with advanced gastrointestinal malignancies with ALK and ROA1 rearrangement, and for whom there is no available therapeutic option.
Timeline
- Start
- 2015-12
- Primary completion
- 2018-03-29
- Completion
- 2018-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceritinib | Small molecule | — | Oral |